title: [Comparison of effectiveness and safety of different treatment modes for limited-stage small cell lung].
abstract: OBJECTIVE
  To compare the effectiveness and safety of different treatment modes for limited-stage small cell lung cancer(SCLC).
  
  
  METHODS
  The clinical data of 171 SCLC patients who had received different therapies were retrospectively analyzed.
  
  
  RESULTS
  Of these 171 patients,55 had received concurrent radiochemotherapy,66 received sequential radiochemotherapy,and 50 received chemotherapy alone. For these 171 patients,the overall response rate(ORR)was 73.1%,overall survival(OS)and progression-free survival(PFS)were 23.5 months and 15.2 months,respectively,and the 1-,3-,and 5-year survival rates were 76.2%,30.4%,and 16.3%,respectively. For the concurrent group,sequential group,chemotherapy alone group,the median OS were 30.6,23.1,and 19.1 months,the median PFS were 19.7,13.3,and 11.5 months,and the 5-year survival rate was 28.7%,13.6%,and 9.4%,respectively(all P<0.05). The main toxic effects were myelosuppression,radiation pneumonia,and radiation esophagitis. The incidences of 1-2 grade myelosuppression were 92.7%,89.4%,and 92% in the concurrent group,sequential group,and chemotherapy alone group(P=0.25). For concurrent group and sequential group,the incidence of 1 grade radiation pneumonia were 47.2% and 50%,respectively(P=0.61),whereas the incidence of 1-2 grade radiation esophagitis were 94.5% and 75.8%(P=0.02). Multivariate analysis showed that gender,ECOG score,TNM stage,and thoracic radiation therapy were the independent prognostic factors for SCLC.
  
  
  CONCLUSIONS
  Concurrent radiochemotherapy is the treatment of choice for SCLC patients because it can improve the survival with tolerable toxicities.
authors.affiliation: Department of Radiation Oncology, Cancer Institute and Hospital, CAMS and PUMC, Beijing, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Shen
authors.forename: Lu-hua
authors.initials: LH
authors.lastname: Wang
authors.forename: Fu-quan
authors.initials: FQ
authors.lastname: Zhang
authors.forename: Meng-zhao
authors.initials: MZ
authors.lastname: Wang
authors.forename: Zhang
authors.initials: Z
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D059248:Chemoradiotherapy / Q000379:methods; D004358:Drug Therapy / Q000379:methods; D004941:Esophagitis / Q000453:epidemiology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017564:Radiation Pneumonitis / Q000453:epidemiology; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate